EP300 and cancer: Figure 6F summarizes the results of these studies. We found that the inhibition of β-catenin in cancer cells leads to the dissociation and removal of β-catenin-TCF4-p300 complexes from the CEGRs/ALCDs in the GPC3 gene and from the AFP promoter, resulting in the suppression of these genes and subsequent reduction of AFP and GPC3 mRNAs and proteins.